title: Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.
abstract: Several groups have shown that that the BCR-ABL1 transcript level measured at 3 or 6 months after starting treatment with tyrosine kinase inhibitors strongly predicts clinical outcomes for patients with chronic myeloid leukemia. In this work, we asked whether the prognostic value of the 3-month transcript level could be improved by combining the 3- and 6-month results. We classified patients treated with imatinib and patients treated with dasatinib according to their transcript levels at 3 months and 6 months. The patients who met the 3-month landmark but failed the 6-month one had outcomes identical to those of patients who met both landmarks, whereas the patients who failed the first landmark but met the second one had prognoses similar to those who failed both landmarks. In summary, early intervention strategies can be based robustly just on the transcript level at 3 months. This trial was registered at www.clinicaltrials.gov as # NCT01460693.
authors: Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom.
authors: Pratap
authors: P
authors: Neelakantan
authors: Gareth
authors: G
authors: Gerrard
authors: Claire
authors: C
authors: Lucas
authors: Dragana
authors: D
authors: Milojkovic
authors: Philippa
authors: P
authors: May
authors: Lihui
authors: L
authors: Wang
authors: Christos
authors: C
authors: Paliompeis
authors: Marco
authors: M
authors: Bua
authors: Alistair
authors: A
authors: Reid
authors: Katayoun
authors: K
authors: Rezvani
authors: Stephen
authors: S
authors: O'Brien
authors: Richard
authors: R
authors: Clark
authors: John
authors: J
authors: Goldman
authors: David
authors: D
authors: Marin
mesh_terms: D000070:Acebutolol / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use*; D000069439:Dasatinib; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D005820:Genetic Testing / Q000379:methods; D006801:Humans; D000068877:Imatinib Mesylate; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy* / Q000235:genetics*; D010879:Piperazines / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use*; D012307:Risk Factors; D013844:Thiazoles / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000070:Acebutolol; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D000069439:Dasatinib
references: Blood. 2006 Jun 1;107(11):4532-9
references: 16469872
references: J Clin Invest. 2011 Jan;121(1):396-409
references: 21157039
references: Blood. 2012 Jul 12;120(2):291-4
references: 22645182
references: J Clin Oncol. 2008 Jul 10;26(20):3358-63
references: 18519952
references: J Clin Oncol. 2012 Jan 20;30(3):232-8
references: 22067393
references: Hematology Am Soc Hematol Educ Program. 2012;2012:115-21
references: 23233569
references: N Engl J Med. 2010 Jun 17;362(24):2260-70
references: 20525995
references: Blood. 2002 Jan 1;99(1):319-25
references: 11756187
references: Leukemia. 2012 Sep;26(9):2096-102
references: 22446502
references: Blood. 2012 Feb 9;119(6):1501-10
references: 22184410
references: N Engl J Med. 2010 Jun 17;362(24):2251-9
references: 20525993